Your Global Leader in Stem Cell Market Research
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for cancer and immune disorders, announced the U.S. FDA has cleared its Investigational New Drug (IND) application for FT538.
FT538 is the first CRISPR-edited, iPSC-derived cell therapy under development worldwide. [Read more…]
Author: Jean-Philippe Richard, Ph. D. ([email protected])
Parkinson’s Disease (PD) affects some 10 million people worldwide, most commonly in patients over the age of 50. PD is associated with the loss of dopaminergic neurons in the substantia nigra region of the brain, leading to the characteristic tremors in the extremities, among other symptoms. There is a need for models of PD to help discover new therapies. To help address this need, we generated and characterized iPSC-derived PD dopaminergic neurons as a test case for functional neural differentiation. [Read more…]
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
PALO ALTO, Calif., May 15, 2020 — I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up focusing on Nobel Prize-wining technology “induced pluripotent stem cell (iPSC)” began manufacturing clinical-grade iPSCs. We are now officially taking orders for custom manufacturing of clinical-grade iPSCs from institutions around the world.
On March 11, 2020, the company received a license to manufacture clinical-grade cells from Japan’s Ministry of Health, Labour and Welfare for its cell manufacturing facility located in Kyoto, Japan. [Read more…]
Several therapeutic applications are now being studied in preclinical tests using induced pluripotent stem cell (iPSC) derived cells for their potential to produce functional cells capable of replacing damaged or dysfunctional tissues in patients. The first clinical trial using iPSCs started in 2008, and now in 2020, the number has risen to 53.
The early clinical trials did not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines were created from specific patient populations to determine if these cell lines could be a good model for a disease of interest. [Read more…]
